BRCA1 and BRCA2

Posted 1 year ago by Wales Gene Park

PARTNER: Randomised, phase II/III, 3 stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or Gbrca Surgery is often used for early breast cancers. Sometimes you have chemotherapy before surgery. This is called neo adjuvant chemotherapy. It can shrink the cancer and make the surgery more successful. In this trial, researchers are looking at whether adding a drug called olaparib (also called Lynparza) improves neo adjuvant chemotherapy. Olaparib is a type of biological therapy called a PARP-1 inhibitor.  PARP is a protein that helps cells to repair. Doctors think that olaparib can stop the cancer cells from repairing themselves. In this trial, people have 1 of the following: chemotherapy chemotherapy with olaparib The chemotherapy drugs used in this trial are: paclitaxel carboplatin These are commonly used to treat breast cancer but are not routinely used to...

 BRCA1 and BRCA2 /  Wales Wide

Posted 1 year ago by Wales Gene Park

EMBRACE: Epidemiological study of BRCA1 and BRCA2 mutation carriers This study collects information about people who have inherited faulty breast cancer genes. A small number of men and women have inherited faulty genes which means that they at an increased risk of developing certain cancers. Two of these genes are called BRCA1 and BRCA2. When someone has a fault in these genes they are more likely to develop cancers of the breast, ovary or prostate. The EMBRACE study, which stands for Epidemiological Study of Familial Breast Cancer, aims to create a register of families who have a fault in these genes. The people taking part will be asked to fill in a questionnaire and to give a small sample of blood, which will be looked at in a laboratory. With this information they hope to find out How many people go on to develop cancer What other factors may play a part...

 BRCA1 and BRCA2 /  Cardiff


No post found